Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative
Erlan Sanchez,Tim Wilkinson,Gillian Coughlan,Saira Mirza,Andrée-Ann Baril,Joel Ramirez,Malcolm A Binns,Sandra E Black,Michael Borrie,Allison A Dilliott,Roger A Dixon,Dar Dowlatshahi,Sali Farhan,Elizabeth Finger,Corinne E Fischer,Andrew Frank,Morris Freedman,Rafaella A Goncalves,David A Grimes,Ayman Hassan,Robert A Hegele,Sanjeev Kumar,Anthony E Lang,Connie Marras,Paula M McLaughlin,Joseph B Orange,Stephen H Pasternak,Bruce G Pollock,Tarek K Rajji,Angela C Roberts,John F Robinson,Ekaterina Rogaeva,Demetrios J Sahlas,Gustavo Saposnik,Michael J Strong,Richard H Swartz,David F Tang-Wai,Maria Carmela Tartaglia,Angela K Troyer,Hlin Kvartsberg,Henrik Zetterberg,Douglas P Munoz,ONDRI Investigators,Mario Masellis
DOI: https://doi.org/10.1002/alz.13560
Abstract:Introduction: We investigated whether novel plasma biomarkers are associated with cognition, cognitive decline, and functional independence in activities of daily living across and within neurodegenerative diseases. Methods: Glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), phosphorylated tau (p-tau)181 and amyloid beta (Aβ)42/40 were measured using ultra-sensitive Simoa immunoassays in 44 healthy controls and 480 participants diagnosed with Alzheimer's disease/mild cognitive impairment (AD/MCI), Parkinson's disease (PD), frontotemporal dementia (FTD) spectrum disorders, or cerebrovascular disease (CVD). Results: GFAP, NfL, and/or p-tau181 were elevated among all diseases compared to controls, and were broadly associated with worse baseline cognitive performance, greater cognitive decline, and/or lower functional independence. While GFAP, NfL, and p-tau181 were highly predictive across diseases, p-tau181 was more specific to the AD/MCI cohort. Sparse associations were found in the FTD and CVD cohorts and for Aβ42/40 . Discussion: GFAP, NfL, and p-tau181 are valuable predictors of cognition and function across common neurodegenerative diseases, and may be useful in specialized clinics and clinical trials.